collection
MENU ▼
Read by QxMD icon Read
search

T

shared collection
3 papers 0 to 25 followers
By Xavier Uyaguari Médico
https://www.readbyqxmd.com/read/27574741/lung-cancer-current-therapies-and-new-targeted-treatments
#1
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies...
August 26, 2016: Lancet
https://www.readbyqxmd.com/read/26351332/cost-effectiveness-of-pertuzumab-in-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer
#2
RANDOMIZED CONTROLLED TRIAL
Ben Y Durkee, Yushen Qian, Erqi L Pollom, Martin T King, Sara A Dudley, Jenny L Shaffer, Daniel T Chang, Iris C Gibbs, Jeremy D Goldhaber-Fiebert, Kathleen C Horst
PURPOSE: The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. We performed a cost-effectiveness analysis to assess the value of adding pertuzumab. PATIENT AND METHODS: We developed a decision-analytic Markov model to evaluate the cost effectiveness of docetaxel plus trastuzumab (TH) with or without pertuzumab in US patients with metastatic breast cancer...
March 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/25442815/ca-19-9-as-a-marker-in-addition-to-cea-to-monitor-colorectal-cancer
#3
Jolanda Stiksma, Diana C Grootendorst, Peter Willem G van der Linden
BACKGROUND: Carcinoembryonic antigen is the commonly used tumor marker in patients with colorectal cancer, and CA 19-9 might be an additional marker. The aim of this retrospective study was to investigate whether CA 19-9 levels can be used to monitor the disease process in patients with colorectal cancer who had no elevated CEA levels. The secondary aim was to determine if preoperative increased levels of CEA and CA 19-9 were associated with mortality. MATERIALS AND METHODS: Two sets of data from patients with histologically confirmed colorectal cancer, were included in a single-center study...
December 2014: Clinical Colorectal Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"